<DOC>
	<DOCNO>NCT00385398</DOCNO>
	<brief_summary>RATIONALE : Treatment radiosurgery , temozolomide , erlotinib may affect brain function ( ability think , learn , remember , judge ) patient non-small cell lung cancer brain metastasis . A study evaluate brain function may help doctor plan best treatment . PURPOSE : This phase II trial study effect radiosurgery , temozolomide , erlotinib brain function patient non-small cell lung cancer brain metastasis .</brief_summary>
	<brief_title>QOL-Stereotactic RadioSurgery , Temozolomide + Erlotinib-Rx 1-3 Brain Metastases NSCLC</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine effect stereotactic radiosurgery , temozolomide , erlotinib hydrochloride cognitive function patient non-small cell lung cancer brain metastasis . Secondary - Determine feasibility safety regimen , term tumor response , time tumor progression brain , survival , physical functioning , quality life , patient . - Determine frequency O6-methylguanine-DNA methyltransferase promoter methylation patient . OUTLINE : This multicenter study . Patients undergo stereotactic radiosurgery day -7 . Patients receive oral temozolomide daily day 1-5 oral erlotinib hydrochloride daily day 1-23 . Treatment temozolomide erlotinib hydrochloride repeat every 28 day absence disease progression unacceptable toxicity . Patients undergo cognitive function evaluation measure Mini-Mental Status Exam administration scoring ; quality life assessment measure Functional Assessment Cancer Therapy subscale ; physical functioning assessment measure Katz index activity daily live Karnofsky performance status baseline every 8 week study treatment . Tumor tissue examine O6-methylguanine-DNA methyltransferase ( MGMT gene ) promotor methylation . After completion study therapy , patient follow every 3 month . PROJECTED ACCRUAL : A total 54 patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm nonsmall cell lung cancer meeting follow criterion : One 3 brain metastasis , meet follow criterion : No large 3 cm Greater 5 mm optic apparatus Not involve brainstem , pons , medulla , midbrain Stable systemic disease past 3 month Less 3 month since completion primary treatment Measurable CNS disease define RECIST criterion No leptomeningeal disease document MRI cerebrospinal fluid cytologic evaluation PATIENT CHARACTERISTICS : Life expectancy ≥ 12 week Karnofsky performance status 60100 % Absolute neutrophil count ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Hemoglobin ≥ 10 g/dL Bilirubin ≤ 1.5 time upper limit normal ( ULN ) AST ≤ 3.0 time ULN Serum creatinine ≤ 1.5 mg/dL Creatinine clearance &gt; 50 mL/min No malignancy within past 5 year , except adequately treat basal cell squamous cell skin cancer carcinoma situ cervix No concurrent major medical illness psychiatric impairment , investigator 's opinion , would preclude study participation No concurrent active infection No know HIV positivity Not pregnant nursing Negative pregnancy test Fertile patient must use effective nonhormonal contraception 3 month completion study treatment PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior complete resection brain metastases No prior brain radiation therapy No prior temozolomide erlotinib hydrochloride No concurrent enzymeinducing antiepileptic drug No concurrent recombinant interleukin11 No concurrent anticancer investigational commercial agent therapy , include chemotherapy , immunotherapy , hormonal cancer therapy , radiation therapy , cancer surgery No concurrent enrollment another clinical trial Surgery symptomatic brain lesion prior radiosurgery allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>tumor metastatic brain</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
</DOC>